4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders Growth (1y) (2021 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 95.87% |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -33.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -33.44% |
| Mar 31, 2026 | -43.33% |
| Dec 31, 2025 | 139.05% |
| Sep 30, 2025 | -29.73% |
| Jun 30, 2025 | -56.38% |
| Mar 31, 2025 | -48.06% |
| Dec 31, 2024 | -53.86% |
| Sep 30, 2024 | -327.49% |
| Jun 30, 2024 | -18.02% |
| Mar 31, 2024 | -12.97% |
| Dec 31, 2023 | -17.91% |
| Sep 30, 2023 | 60.08% |
| Jun 30, 2023 | -5.45% |
| Mar 31, 2023 | -8.90% |
| Dec 31, 2022 | -9.15% |
| Sep 30, 2022 | -15.52% |
| Jun 30, 2022 | -270.09% |
| Mar 31, 2022 | -60.54% |
| Dec 31, 2021 | -22.08% |
| Sep 30, 2021 | -183.91% |